Optimal Management of Methotrexate Intoxication in a Child with Osteosarcoma

Annals of Pharmacotherapy

Volumn 38, Issue 3, 2004, Pages 422-427

  Peyriere, Hélène ^a   Cociglio, Marylène ^a   Margueritte, Geneviève ^b   Vallat, Catherine ^c   Blayac, Jean Pierre ^a   Hillaire Buys, Dominique ^a  

^a LAPEYRONIE HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c HÔPITAL SAINT ELOI   (France)

Author keywords

Child; Methotrexate; Osteosarcoma

Indexed keywords

AMINOPHYLLINE; BICARBONATE; CARBOXYPEPTIDASE G2; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HOMOCYSTEINE; IFOSFAMIDE; METHOTREXATE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ALKALINIZATION; ARTICLE; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; CHILDHOOD CANCER; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INTOXICATION; DRUG MEGADOSE; DRUG TOLERABILITY; HISPANIC; HUMAN; LIMB SALVAGE; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT OUTCOME; URINE;

ADOLESCENT; BONE NEOPLASMS; HEPATITIS, TOXIC; HUMANS; KIDNEY FAILURE, ACUTE; MALE; METHOTREXATE; MOUTH MUCOSA; OSTEOSARCOMA; STOMATITIS;

EID: 1242293861     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D237     Document Type: Article

References (23)

1. Jaffe N, Frei E, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974;291:994-7.
2. Chu E, Allegra CJ. Antifolates. In: Chabner BA, Longo DL. eds. Cancer chemotherapy and biotherapy: principles and practice. 2nd ed. Philadelphia: JB Lippincott, 1995:109-48.
3. Chan H, Evans WE, Pratt CB. Recovery from toxicity associated with high-dose methotrexate: prognostic factors. Cancer Treat Rep 1977;61:797-804.
4. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M, et al. Carboxypeptidase G2. thymidine and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol 1997;15:2125-34.
5. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7.
6. Guttormsen AB, Ueland PM, Lonning PE, Mella O, Refsum H. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clin Chem 1998;44:1987-9.
7. Refsum H, Ueland PM, Kvinnsland S. Acute and long term effects of high-close methotrexate treatment on homocysteine in plasma and urine. Cancer Res 1986:46:5385-91.
8. Broxson EH, Stork LC, Allen RH, Stabler SP. Kolhouse JF. Changes in plasma methionine and total homocysteine levels in patients receiving methotrexate infusions. Cancer Res 1989;49:5879-83.
9. Cociglio M, Hillaire-Buys D, Alric R. Determination of methotrexate and 7-hydroxymethotrexate by liquid chromatography for routine monitoring of plasma levels. J Chromatogr B Biomed Appl 1995;674:101-10.
10. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
11. Rosen G, Caparros B, Huvos A, Kosloff C, Nirenberg A, Cacavio A, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982;49:1221-30.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
13. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978;41:36-51.
14. Saeter G, Alvegard TA, Elomaa I, Stenwig AE, Holmstrom T, Solheim OP. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol 1991;9:1766-75.
15. Ridolfi L, Barisone E, Vivalda M, Vivenza C, Brach Del Prever A, Leone L, et al. Toxicity of high dose methotrexate repeated infusions in children treated for acute lymphoblastic leukemia and osteosarcoma. Minerva Pediatr 1996;48:193-200.
16. Relling MW, Fairclough D, Ayers D, Crom WR, Rodman JH, Pui CH, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994:12:1667-72.
17. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-9.
18. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercari M, et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubucin, and cisplatin. J Clin Oncol 1998;16:658-63.
19. Delepine N, Delepine G, Desbois JC. Prognostic value of drug intensity (DI) and seric intensity (SI) of methotrexate in osteosarcoma (abstract). Proc Am Soc Clin Oncol 1992;11:47.
20. Smeland E, Bremnes RM, Andersen A, Jaeger R, Eide TJ, Huseby NE, et al. Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat. Cancer Chemother Pharmacol 1994;34:119-24.
21. Zoubek A, Zaunschirm HA, Lion T, Fischmeister G, Vollnhofer G, Gadner H, et al. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol 1995;12:471-7.
22. Peyriere H, Poiree M, Cociglio M, Margueritte G, Hansel S, Hillaire-Buys D. Reversal of neurologic disturbances related to high-dose methotrexate by aminophylline. Med Pediatr Oncol 2001;36:662-4.
23. Cronstein BN, Naime D, Ostad E. The anti-inflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leucocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675-82.